Latest MS research news

Featured

Global response to progressive MS challenge

Global experts from the Progressive MS Alliance are meeting in London in April and May to review the applications they have received for funding.

From MSIF

Latest MS research news | 22 July 2014

Perivascular spaces in MS patients at 7 Tesla MRI: a marker of neurodegeneration?

MS patients displayed more Virchow-Robin spaces (VRS) compared to healthy controls, especially in superior areas of the brain. VRS in MS patients were associated with supratentorial brain atrophy, but not with lesion load.

From MSIF

Latest MS research news | 22 July 2014

Bringing CLARITY to gray matter atrophy

The use of both MRI and CLARITY represents a novel approach to better discern neuropathological processes in intact tissues in 3D in a variety of neurodegenerative diseases, like multiple sclerosis.

From MSIF

Latest MS research news | 22 July 2014

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene

JCV GCN should be considered in patients on natalizumab presenting with progressive cerebellar symptoms and cerebellar atrophy, and is associated with mutations in the JCV VP1 gene.

From MSIF

Latest MS research news | 14 July 2014

Balance exercise program reduced falls in people with MS

The seven-week twice-weekly group exercise (CoDuSe) program reduced falls and proportion of fallers and improved balance performance in people with mild-to-moderate MS, but did not significantly alter perceived limitations in walking and balance confidence.

From MSIF

Latest MS research news | 14 July 2014

Efficacy of vaccination against influenza in patients with MS

This review highlights the importance of evaluating the efficacy of vaccinations in patients treated with immunosuppressant drugs. Most MS drugs appear not to be associated with a reduced response to influenza vaccination, with the notable exception of mitoxantrone and glatiramer acetate.

From MSIF

Latest MS research news | 14 July 2014

MS patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy

This study is the first to analyze the relationship between oligoclonal immunoglobulin G bands and volume of multiple brain structures. The authors report significant magnetic resonance imaging differences between MS patients carrying versus lacking oligoclonal cerebrospinal fluid immunoglobulin G bands

From MSIF

Latest MS research news | 09 July 2014

Investigation of magnetization transfer ratio-derived pial and subpial abnormalities in the MS spinal cord

The study suggests that abnormalities in a region involving the pia mater and subpial cord occur early in the course of multiple sclerosis and are more marked in patients with a progressive course.

From MSIF

Latest MS research news | 09 July 2014

Treatment of relapsing-temitting MS after 24 doses of Natalizumab

Careful individual evaluation of progressive multifocal leukoencephalopathy risk based on the risk factors is needed, and natalizumab discontinuation can be reasonably advised for patients whose risk is considered too high.

From MSIF

Latest MS research news | 09 July 2014

Increased autotaxin activity in MS

ATX activity is significantly higher in MS patients than those patients diagnosed with OND. It is possible that inhibition of the Autotaxin may decrease the rate of MS relapses/progression.

From MSIF

Latest MS research news | 02 July 2014

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome

The authors don’t find a significant association between the development of global, tissue-specific and regional brain atrophy and cognitive deterioration in treated CIS patients over 24 months.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial